<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631720</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT CTOT-20</org_study_id>
    <nct_id>NCT02631720</nct_id>
  </id_info>
  <brief_title>CLAD Phenotype Specific Risk Factors and Mechanisms</brief_title>
  <official_title>A Prospective Multicenter Observational Cohort Study to Define the Risks Factors, Mechanisms, and Manifestations of Chronic Lung Allograft Dysfunction (CLAD) Phenotypes (CTOT-20)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trials in Organ Transplantation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While many patients experience benefits from transplant, complications such as infections and
      lung rejection may affect long term survival and quality of life. In this study doctors are
      looking at a complication called Chronic Lung Allograft Dysfunction (CLAD). CLAD is thought
      to be chronic rejection of the lung by the immune system and is the leading cause of death
      after lung transplantation.

      The purpose of this study is to help doctors determine:

        -  why some people get CLAD and others do not

        -  how patients who get CLAD do after CLAD is diagnosed

        -  how CLAD may affect quality of life
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, prospective, multicenter study of 800 newly transplanted adult,
      first lung transplant recipients that will collect longitudinal clinical data, patient
      reported quality of life (QOL) data, and serial biological samples to determine the risk
      factors, pathophysiology, and manifestations of restrictive chronic lung allograft
      dysfunction (RCLAD) and bronchiolitis obliterans syndrome (BOS). Anticipated participant
      accrual is within three years of study start‐up. The total study duration is five years.
      Participants will be followed a minimum of 2 and a maximum of 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time from transplant to Restrictive Chronic Lung Allograft Dysfunction (RCLAD) or Bronchiolitis Obliterans Syndrome (BOS).</measure>
    <time_frame>90 days post-transplant until study completion or participant withdrawal (up to 5 years post-transplant)</time_frame>
    <description>First occurrence of either phenotype.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemokine/cytokine Quantification of Type 1 and Type 17 immune profile proteins</measure>
    <time_frame>Baseline until study completion or participant withdrawal (up to 5 years post-transplant)</time_frame>
    <description>Measured in the Bronchoalveolar lavage (BAL) supernatant.using standard Luminex and ELISA commercial assays</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longitudinal Quality of life (QOL) trajectory</measure>
    <time_frame>Baseline until study completion or participant withdrawal (up to 5 years post-transplant)</time_frame>
    <description>As serially assessed by the 36-item Short Form Survey (SF‐36) and the St. George's Respiratory Questionnaire (SGRQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from transplant to death or retransplant</measure>
    <time_frame>Until study completion or participant withdrawal (up to 5 years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from CLAD onset to the occurrence of death or retransplant</measure>
    <time_frame>CLAD onset until study completion or participant withdrawal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal Pulmonary function test (PFT) trajectory</measure>
    <time_frame>Baseline until study completion or participant withdrawal (up to 5 years post-transplant)</time_frame>
    <description>As assessed by Serial Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Lung Transplant</condition>
  <condition>Post Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>Adult Lung Transplant Recipients</arm_group_label>
    <description>Adult lung transplant recipients undergoing lung transplant at each of the participating centers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <arm_group_label>Adult Lung Transplant Recipients</arm_group_label>
    <other_name>Phlebotomy</other_name>
    <other_name>Venipuncture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopy</intervention_name>
    <arm_group_label>Adult Lung Transplant Recipients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral whole blood samples: DNA, RNA, Plasma, Serum Bronchoalveolar lavage (BAL):
      aliquots with DNA, cells, supernatant
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult lung transplant recipients undergoing lung transplant at each of the participating
        centers.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Individuals who meet all of the following criteria are eligible for enrollment as study
        participants:

          1. Subject must be able to understand and provide written informed consent.

          2. Anticipated listing for lung transplantation OR listed for lung transplant or is
             within 1 month of having received a single or bilateral cadaveric donor lung
             transplant.

          3. Undergoing first lung transplant operation.

          4. Transplant surgery to be performed or performed at enrolling center.

               -  Note: Concurrent participation in immune monitoring studies or interventional
                  device trials are permitted.

        Exclusion Criteria:

        Individuals who meet any of the following criteria are not eligible for enrollment as study
        participants:

          1. Multi-organ recipient.

          2. Prior recipients of any solid organ transplant, including prior lung transplant.

          3. Prior or concurrent recipient of bone marrow transplant.

          4. HIV infection.

          5. Pregnant or planned pregnancy.

          6. Any condition which the investigators feel would make it unlikely for the recipient to
             complete follow up procedures or complete the study.

          7. Participation in an investigational drug trial at the time of enrollment visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott M Palmer, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Belperio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Callahan</last_name>
      <phone>310-794-2466</phone>
      <email>ecallahan@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>John Belperio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joby Mathew</last_name>
      <phone>410-550-6458</phone>
      <email>jmathe27@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Pali Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allie Frear</last_name>
      <phone>919-684-8914</phone>
      <email>allie.frear@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>John M Reynolds, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bette Maierson</last_name>
      <phone>216-444-2901</phone>
      <email>maierse@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Marie Budev, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anam Islam</last_name>
      <phone>(416) 340-4800</phone>
      <phone_ext>6740</phone_ext>
      <email>anam.islam@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Lianne Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT)</description>
  </link>
  <link>
    <url>http://www.ctotstudies.org/</url>
    <description>Clinical Trials in Organ Transplantation (CTOT)</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lung Allograft Dysfunction (CLAD)</keyword>
  <keyword>Restrictive chronic lung allograft dysfunction (RCLAD)</keyword>
  <keyword>Bronchiolitis Obliterans Syndrome (BOS)</keyword>
  <keyword>CLAD risk factors</keyword>
  <keyword>observational study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

